OBI Pharma 
Welcome,         Profile    Billing    Logout  
 5 Products   0 Diseases   5 Products   6 Trials   106 News 


«123»
  • ||||||||||  adagloxad simolenin (OBI-822/821) / OBI Pharma
    Globo H: A Globo series glycosphingolipid target antigen in breast cancer (Hall 1) -  Oct 26, 2021 - Abstract #SABCS2021SABCS_1310;    
    Adagloxad simolenin (AS/OBI-822) is a Globo H conjugate vaccine that when administered in combination with the adjuvant OBI-821 results in anti‒Globo H IgM and IgG humoral immune responses...To enter the GLORIA study, patients must have a centrally confirmed Globo H IHC H-score of ≥15, and it is anticipated that approximately 40% of patients screened will have this level of expression. The GLORIA study is presently enrolling patients in 7 countries, with another 9 countries anticipated to begin recruiting in 2021.
  • ||||||||||  OBI-3424 / OBI Pharma
    Journal:  A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity. (Pubmed Central) -  Aug 7, 2021   
    In the combination therapy, we showed that 3424 could enhance the efficacy of the standard care of chemotherapy in the CDX models. The results described here highlight that 3424 exhibits AKR1C3-dependent cytotoxicity in vitro and anti-tumor activity in vivo in a wide range of human cancer types, which support further development of 3424 as an anti-cancer agent for treating different types of cancers and the use of AKR1C3 as a biomarker to profile cancer patients and further guide patient selection for therapy with 3424.
  • ||||||||||  OBI-999 / OBI Pharma
    Enrollment closed, Metastases:  Phase 1/2 Study of OBI-999 in Patients with Advanced Solid Tumors (clinicaltrials.gov) -  Jul 9, 2021   
    P1/2,  N=185, Active, not recruiting, 
    The results described here highlight that 3424 exhibits AKR1C3-dependent cytotoxicity in vitro and anti-tumor activity in vivo in a wide range of human cancer types, which support further development of 3424 as an anti-cancer agent for treating different types of cancers and the use of AKR1C3 as a biomarker to profile cancer patients and further guide patient selection for therapy with 3424. Recruiting --> Active, not recruiting
  • ||||||||||  OBI-999 / OBI Pharma, OBI-833 / OBI Pharma
    [VIRTUAL] Globo H expression in metastatic colorectal cancer (CRC). () -  Apr 28, 2021 - Abstract #ASCO2021ASCO_2355;    
    The association with different cell populations suggests manipulating the cellular balance in the TME as an approach to improve the efficacy of treatment . NK cell checkpoint inhibitors are in clinical trials and might be utilized in high Globo H cancers; treatments inducing DCs in tumors have been shown to enhance responses to BRAF and PD-L1 blockade and might be applicable in the context of Globo H immunotherapy to overcome Treg immune suppression .
  • ||||||||||  OBI-3424 / OBI Pharma
    Journal:  An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL. (Pubmed Central) -  Apr 28, 2021   
    In this study, AST-006 demonstrated potent anti-tumor activity against different T-ALL cell lines in vitro and in vivo, including patient-derived xenograft (PDX) model. AST-006 also exhibited minimal cytotoxicity against primary human T-cells in vitro and lymphocytes in cynomolgus monkeys in vivo, indicating that AST-006 is a promising therapeutic for T-ALL.
  • ||||||||||  OBI-998 / OBI Pharma
    [VIRTUAL] Preclinical characterization of a novel SSEA-4-targeting antibody drug conjugate, OBI-998 () -  Mar 11, 2021 - Abstract #AACR2021AACR_2050;    
    Furthermore, OBI-998 showed a high level of deposition and a persistent presence of MMAE in tumors and significant anti-tumor efficacy in a variety of animal models. Taken together, these results support the further development of OBI-998 as a therapeutic agent for SSEA-4-targeting cancer therapy.
  • ||||||||||  OBI-3424 / OBI Pharma
    [VIRTUAL] Selective and broad anti-tumor activity of AKR1C3-activated prodrug AST-3424/OBI-3424 () -  Mar 11, 2021 - Abstract #AACR2021AACR_804;    
    In the combination therapy, we have showed that 3424 could enhance the efficacy of the standard care of chemotherapy in the CDX models of VCaP CRPC, SNU-16 gastric, and A498 renal cell carcinoma. In conclusion, the results described here highlight that 3424 exhibits AKR1C3-dependent cytotoxicity in vitro and anti-tumor activity in vivo in a wide range of human cancer types, which support further development of 3424 as an anti-cancer agent for treating different types of cancer and the use of AKR1C3 as a biomarker to profile cancer patients and further guide patient selection for therapy with 3424.
  • ||||||||||  OBI-3424 / OBI Pharma
    Preclinical, Journal:  Life history and habitat do not mediate temporal changes in body size due to climate warming in rodents. (Pubmed Central) -  Oct 8, 2020   
    Firstly, taking advantage of new data from museum collections spanning the last 106 years, we investigated geographical and temporal variation in cranial size (a proxy for body size) in six African rodent species of two murid subfamilies (Murinae and Gerbillinae) of varying life history, degree of commensality, range size, and habitat...Secondly, in order to further test this hypothesis, we incorporated our data into a meta-analysis based on published literature on temporal responses in rodents, resulting in a combined dataset for 50 species from seven families worldwide; among these, 29 species showed no significant change, eight showed a significant increase in size, and 13 showed a decline in size. Using a binomial logistic regression model for these metadata, we found that none of our chosen life history or habitat predictors could significantly explain the probability of a temporal response to climate warming, reinforcing our conclusion based on the more detailed data from the six African species.
  • ||||||||||  OBI-3424 / OBI Pharma
    Journal:  Memristive synapses with high reproducibility for flexible neuromorphic networks based on biological nanocomposites. (Pubmed Central) -  Oct 7, 2020   
    These devices show highly reproducible analog resistive switching behaviors with 250 conductance states, low write noise, good write linearity, high retention of more than 104 s and endurance for at least 106 pulses...Simulations including the non-ideal factors prove that the synaptic device array can operate with an online learning accuracy of 94.3%. These findings enable broader applications of biomaterials in flexible memristive devices and neuromorphic systems.
  • ||||||||||  OBI-3424 / OBI Pharma
    Trial completion date, Trial primary completion date, Metastases:  A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors (clinicaltrials.gov) -  Aug 8, 2020   
    P1/2,  N=104, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Nov 2021 --> Mar 2023 | Trial primary completion date: Aug 2021 --> Jan 2023
  • ||||||||||  OBI-999 / OBI Pharma
    Trial completion date, Trial primary completion date, Metastases:  Phase 1/2 Study of OBI-999 in Patients with Advanced Solid Tumors (clinicaltrials.gov) -  Aug 7, 2020   
    P1/2,  N=185, Recruiting, 
    Trial completion date: Nov 2025 --> Dec 2027 Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: Apr 2023 --> Nov 2023